Elizabeth Hickin

Elizabeth Hickin has extensive experience in investor relations and corporate communications, currently serving as Vice President of Investor Relations and Corporate Communications at Tango Therapeutics since March 2025. Previously, Elizabeth held the position of Vice President of Investor Relations at Zentalis Pharmaceuticals and served in various roles at 2seventy bio, including Senior Director and Director of Investor Relations. Elizabeth's career also includes significant contributions at bluebird bio as Director of Investor Relations and Associate Director of Corporate Communications, alongside progressive roles at Takeda Oncology and communications agencies like Waggener Edstrom and LaVoie Group. Elizabeth began a professional journey in investor relations following an earlier role as a Market Data Analyst at UBS Investment Bank after earning a BA in English from Georgetown University and a brief educational stint at the University of Galway.